Clemedi
Clemedi is a Swiss company based in Zurich that develops diagnostics for infectious diseases by combining DNA sequencing and smart software. Their mission is to give the right antibiotics by providing faster, comprehensive diagnostic tests that support targeted therapy, thereby helping to limit antimicrobial resistance. They offer products such as Tuberculini, a diagnostic test for drug-resistant tuberculosis, and are expanding into other infectious diseases including latent tuberculosis, sexually transmitted infections, and hospital-acquired infections. The company is actively involved in product development, market entry, and strategic partnerships, with a focus on improving infectious disease diagnostics through innovative sequencing and bioinformatics technologies.
Industries
Nr. of Employees
small (1-50)
Products
Sequencing-based tuberculosis diagnostic kit (CE‑IVD)
A targeted sequencing workflow and accompanying software for species identification, genotyping/lineage determination, and detection of resistance-associated mutations for a panel of tuberculosis antibiotics directly from patient samples (e.g., sputum) with results reported within ~48 hours. CE‑IVD certified for the EU market.
Clemedi Infectious Disease Diagnostics Platform
A best-in-class platform to diagnose infectious diseases by combining DNA sequencing and artificial intelligence without bacterial culture.
Tuberculosis diagnostic solution
A diagnostic solution that identifies disease-causing Mycobacteria and predicts antibiotic susceptibility to several antibiotics within 24 hours.
Sexually Transmitted Infections (STI) Diagnostic Test
An in vitro diagnostic (IVD) test under development to diagnose STIs directly from patient samples, detecting 13 pathogens and all known markers of resistance.
Tuberculini
An assay for the detection of drug-resistant tuberculosis providing lineage determination and resistance testing for 12 antibiotics, directly from a patient's sputum sample in 48 hours.
Sequencing-based tuberculosis diagnostic kit (CE‑IVD)
A targeted sequencing workflow and accompanying software for species identification, genotyping/lineage determination, and detection of resistance-associated mutations for a panel of tuberculosis antibiotics directly from patient samples (e.g., sputum) with results reported within ~48 hours. CE‑IVD certified for the EU market.
Clemedi Infectious Disease Diagnostics Platform
A best-in-class platform to diagnose infectious diseases by combining DNA sequencing and artificial intelligence without bacterial culture.
Tuberculosis diagnostic solution
A diagnostic solution that identifies disease-causing Mycobacteria and predicts antibiotic susceptibility to several antibiotics within 24 hours.
Sexually Transmitted Infections (STI) Diagnostic Test
An in vitro diagnostic (IVD) test under development to diagnose STIs directly from patient samples, detecting 13 pathogens and all known markers of resistance.
Tuberculini
An assay for the detection of drug-resistant tuberculosis providing lineage determination and resistance testing for 12 antibiotics, directly from a patient's sputum sample in 48 hours.
Services
Provision of reagent kits for targeted sequencing workflows to detect pathogens and resistance markers from clinical samples.
Software to analyze sequencing data and produce species identification and drug-susceptibility reports; available as standalone local install or web-hosted interface.
Commercial agreements to supply components or sell kits under partner branding and to establish distribution channels in target geographies.
Collaboration with clinical laboratories and research partners to perform evaluations, generate analytical/clinical performance data, and support manuscript publication.
Provision of reagent kits for targeted sequencing workflows to detect pathogens and resistance markers from clinical samples.
Software to analyze sequencing data and produce species identification and drug-susceptibility reports; available as standalone local install or web-hosted interface.
Commercial agreements to supply components or sell kits under partner branding and to establish distribution channels in target geographies.
Collaboration with clinical laboratories and research partners to perform evaluations, generate analytical/clinical performance data, and support manuscript publication.
Expertise Areas
- Sequencing-based infectious disease diagnostics
- Antimicrobial resistance detection and interpretation
- Bioinformatics and machine-learning for diagnostics
- Assay development and analytical validation
Key Technologies
- Next-generation sequencing (amplicon/targeted sequencing)
- Highly multiplex PCR
- Pathogen DNA extraction from sputum and blood
- Machine learning for antibiotic susceptibility prediction
News & Updates
Clemedi has signed a license agreement with the Max Planck Society and the Medical University of Vienna to extend its tuberculosis product line to cover latent tuberculosis, enabling detection of M. tuberculosis DNA from blood samples.
Clemedi has developed a next-generation sequencing based test called Tuberculini, optimized for Thermo Fisher Scientific’s Ion GeneStudio S5™ System, capable of recognizing resistance to all major therapeutic agents used to treat tuberculosis.
Company milestones and product development updates
Various updates on product development, market entry, partnerships, and clinical validation efforts from 2021 to 2023.
A quarterly update highlighting increased marketing efforts, participation in trade fairs, and progress in market expansion.
Details on transition from research to sales organization, marketing activities, and new market strategies.
Milestone achievement of bringing Tuberculini to market as a CE-IVD device and product development progress.
Clemedi has signed a license agreement with the Max Planck Society and the Medical University of Vienna to extend its tuberculosis product line to cover latent tuberculosis, enabling detection of M. tuberculosis DNA from blood samples.
Clemedi has developed a next-generation sequencing based test called Tuberculini, optimized for Thermo Fisher Scientific’s Ion GeneStudio S5™ System, capable of recognizing resistance to all major therapeutic agents used to treat tuberculosis.
Company milestones and product development updates
Various updates on product development, market entry, partnerships, and clinical validation efforts from 2021 to 2023.
A quarterly update highlighting increased marketing efforts, participation in trade fairs, and progress in market expansion.
Details on transition from research to sales organization, marketing activities, and new market strategies.
Milestone achievement of bringing Tuberculini to market as a CE-IVD device and product development progress.